Edwards Lifesciences (NYSE:EW) Stock Rating Upgraded by JPMorgan Chase & Co.

Edwards Lifesciences (NYSE:EW) was upgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued on Thursday,Benzinga reports. The brokerage currently has a $100.00 price target on the medical research company’s stock, up from their previous price target of $90.00. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 17.85% from the stock’s previous close.

Several other research firms have also recently weighed in on EW. Robert W. Baird set a $87.00 price target on shares of Edwards Lifesciences and gave the stock a “neutral” rating in a report on Tuesday. Sanford C. Bernstein restated a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. UBS Group set a $92.00 price objective on Edwards Lifesciences in a report on Friday, December 5th. Finally, Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a research note on Thursday. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $93.95.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $84.85 on Thursday. The business’s fifty day moving average is $82.10 and its 200 day moving average is $79.18. The firm has a market cap of $49.24 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 3.84 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm earned $0.67 EPS. The company’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 45,465 shares of company stock valued at $3,804,610. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the business. Keel Point LLC boosted its position in Edwards Lifesciences by 3.9% during the third quarter. Keel Point LLC now owns 5,291 shares of the medical research company’s stock valued at $411,000 after buying an additional 199 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth about $150,000. CTC Alternative Strategies Ltd. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $630,000. Allworth Financial LP boosted its holdings in Edwards Lifesciences by 36.6% during the 3rd quarter. Allworth Financial LP now owns 5,505 shares of the medical research company’s stock valued at $428,000 after acquiring an additional 1,476 shares during the period. Finally, IFP Advisors Inc boosted its holdings in Edwards Lifesciences by 2.4% during the 3rd quarter. IFP Advisors Inc now owns 6,703 shares of the medical research company’s stock valued at $521,000 after acquiring an additional 158 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.